Skip to main content
Clinical Trials/ISRCTN47673027
ISRCTN47673027
Terminated
未知

Minimising the risks of emergence of antibiotic resistance during therapy by precise regimen individualisation and use of combination therapy

orth Bristol NHS Trust0 sites80 target enrollmentApril 26, 2022

Overview

Phase
未知
Intervention
Not specified
Conditions
Pulmonary infection
Sponsor
orth Bristol NHS Trust
Enrollment
80
Status
Terminated
Last Updated
3 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
April 26, 2022
End Date
March 31, 2024
Last Updated
3 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
orth Bristol NHS Trust

Eligibility Criteria

Inclusion Criteria

  • 1\. Intubated patients with clinician suspected Gram\-negative pulmonary infection requiring antibacterial therapy
  • 2\. Adults aged 18 years upwards
  • 3\. Patient admitted to ICU for at least 5 days
  • 4\. Patient ventilated for at least 48 hours
  • Inclusion criteria for analysis:
  • Infection with a piperacillin\-tazobactam and gentamicin susceptible Gram\-negative organism.

Exclusion Criteria

  • 1\. Patients for whom informed consent cannot be obtained
  • 2\. Allergies or intolerance to piperacillin\-tazobactam or gentamicin
  • 3\. Neutropaenic sepsis
  • 4\. Past medical history of cystic fibrosis
  • 5\. Other underlying infections pulmonary process unlikely to respond to piperacillin/tazobactam with or without gentamicin (i.e. tuberculosis, fungal pneumonia)
  • 6\. Subject unlikely to survive longer than 24 hours
  • 7\. Prisoners
  • 8\. Pregnant women
  • 9\. Non\-NHS patients

Outcomes

Primary Outcomes

Not specified

Similar Trials